However, since CDKN2A mutations in squamous cell carcinoma of the skin are reported to be more often point mutations than (large) deletions, we believe that adding CDKN2A point mutations to the panel can give valuable information, especially for vulvar cancer. The gene discussed is CDKN2A; the disease is vulva cancer.